Researchers at Moffitt Cancer Center are studying DYV800, a topical cream designed to reduce tumor acidity and help the ...
FDA accelerated approval covers relapsed/refractory MCL after ≥2 lines including a BTK inhibitor, positioning sonrotoclax as a potential first-in-class BCL-2 option in this setting. Single-arm ...
FDA cleared oral decitabine/cedazuridine plus venetoclax for frontline AML in adults ≥75 years or with comorbidities that make intensive induction inappropriate. Study ASTX727-07 (single-arm, ...
Dr. Susan MacDonald breaks down the TNM staging system (Tumor, Nodes, Metastasis) to help patients understand their clinical ...
Although the oncology community is buzzing with the potential of circulating tumor DNA (ctDNA) to revolutionize breast cancer ...
The second recipe, a turmeric latte, includes milk, turmeric, ginger, cinnamon, black pepper and honey. According to the ...
Led by Dr. Moran Amit, MD Anderson is spearheading a pioneering clinical trial that combines the active ingredient found in so-called "magic mushrooms" with a rigorous psychotherapy framework. This ...
Sharing survivorship narratives over years functioned as peer-to-peer hope provision for others confronting breast cancer or ...
Pancreatic cancer remains one of the most difficult cancers to treat, with many patients facing a high risk of recurrence ...
Molecular/genomic profiling is expanding precision selection of systemic therapy and may enable immunotherapy-driven organ ...
Veppanu represents a scientific milestone as the first-ever proteolysis-targeting chimera (PROTAC) to receive FDA approval.
SEER 1975–2023 analysis demonstrated a long-term mortality inflection from rising rates to sustained declines, with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results